Aarkstore.com - Peripheral Neuropathy and Neuropathic Pain_ 2008 - Current_ pipeline and emerging drugs for the treatment by winaarkstore


									Aarkstore.com announces, a new market research report is available in its vast collection:

  Peripheral Neuropathy and Neuropathic Pain, 2008: Current,
  pipeline and emerging drugs for the treatment of peripheral
               neuropathy and neuropathic pain


This report estimates that Peripheral Neuropathy (PN) and Neuropathic Pain (NP) affect 170 to 270
million individuals globally. PN and NP are causally linked to a number of diseases, however diabetes,
cancer and HIV alone are expected to increase the prevalence of PN and NP by more than 10% by
2012. PN and NP are areas of significant and critical unmet need. There are no cures for PN and NP is
difficult to treat and often unresponsive to all available therapies. Todays armoury of drugs for the
treatment of NP shows significant reliance on second-indication drugs, which were initially developed
to treat other primary indications (e.g. anticonvulsants, antidepressants). This report gives a
comprehensive update on all current drugs, together with the entire drug development pipeline, from
pre-clinical through to Phase III, Registration and initial Launch. The pipeline includes 80 candidates
being developed to treat PN and NP as a primary indication and 60 second-indication drugs. More than
300 patents published in the PN and NP field between 2002 and 2008 have also been assessed and
presented, together with the identification of potential candidate molecules and drug targets which
have not entered the development pipeline, but which may do so in the future. This report was written
to provide a comprehensive update on therapeutic developments relating to PN and NP, both in
tackling its most serious and debilitating symptoms, but also in targeting and potentially correcting the
underlying disease mechanisms. Commercial evaluation and assessments including markets, market
size, market sectors, sales and trends relating to PN and NP are also included in this report.

Drug Targets:

Most current and developmental therapies for neuropathic conditions are directed at NP. Moreover,
many of todays commonly used drugs in this area were developed for other indications, but
subsequently were found to offer useful application in the treatment of NP. These include
anticonvulsants, antidepressants and others. These second indication drugs represent around 10
pharmacological mechanisms including 5 hydroxytryptamine uptake inhibitors, cannabinoid CB1
agonists, carnitine acetyltransferase stimulants, GABA receptor agonists, NMDA antagonist, opioid mu
receptor agonists, sodium channel antagonists, tumour necrosis factor alpha antagonists and others of
unidentified pharmacological activity. In contrast, only a few molecules have been developed
specifically for NP as a primary indication and these include an aldose reductase inhibitor, a membrane
integrity agonist and an opioid kappa receptor agonist. However, the last ten years have seen
important advances in the understanding of peripheral neuropathy and neuropathic pain at the
biological and pathophysiological level and this is reflected in the numbers of new candidates in the
drug development pipeline. Today, there are more than 40 drug types in development for the
treatment of PN or NP as primary indications, more than 30 of which are directed at new drug targets.
Whilst most of these are directed at NP, a number are targeting the underlying disease mechanisms,
offering the hope that NP disease progression may be blocked or even reversed. The development and
extension of new and existing molecules for the treatment of NP and PN as second indication drugs
continues, and collectively these two groups (i.e. primary + secondary indication drugs) represent
over 60 different drug types. Recent patent filings, 2002-2008, show a significant number of other
therapeutic opportunities which have not entered the drug development pipeline, but which may do so
in the future. This report identifies these candidates on the basis of their mechanism of action, drug
target, developmental stage, by company and other relevant areas.

Table of Contents:

Executive Summary

Chapter 1 Cancer Stem Cells (p11)

1.1   Summary
1.2   Introduction
1.3   Cancer Stem Cells
1.4   Different Cancers
1.5   Research and Development

Chapter 2 Research and Development (p20)

2.1   Summary
2.2   Background
2.3   Research
2.4   Drug Development Pipeline

Chapter 3 Discovery & Pipeline (p26)

3.1 Summary
3.2 Targeting CSCs
3.2.1 Resistance
3.2.2 The Stem Cell Niche
3.2.3 Salinomycin
3.2.4 Metabotropic Receptors
3.2.5 Telomerase
3.2.6 Notch
3.2.7 Hedgehog, Wnt and mTOR
3.2.8 Bmi-1 Gene
3.2.9 Viruses
3.2.10 Metastasis and Invasion
3.2.11 MicroRNAs
3.2.12 Interleukin-4
3.2.13 L1CAM
3.2.14 Thymosin beta4 (TB4)
3.2.15 EpCAM

More Related Reports :

 Biomarkers in Parkinsons Disease, 2011

 Biomarkers in Breast Cancer, 2011

 Stroke: Competing Treatments and Market Entry Considerations

 Neuropathic Pain: Competing Treatments and Market Entry Considerations
 Hypertension: Competing Treatments and Market Entry Considerations

 Alzheimers Disease: Competing Treatments and Market Entry Considerations

 Targeting Cancer Stem Cells: Therapeutic Strategies, Pipeline, Biomarkers and Opportunities

  Peripheral Neuropathy and Neuropathic Pain, 2008: Current, pipeline and emerging drugs for the
treatment of peripheral neuropathy and neuropathic pain

 Alzheimers Disease: Markets, Pipeline and Opportunities 2009

 Cancer Drug Resistance

 Antibiotics and Drug Resistance 2008

For More details about above & other Reports plz contact :



Contact: Marketing team


Email: enquiry@aarkstore.com

URL: http://www.aarkstore.com/




To top